




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 257/02, A61K 49/00, G01N 24/08, C07F 9/38</b>	<b>A2</b>	(11) International Publication Number: <b>WO 99/35133</b>
		(43) International Publication Date: 15 July 1999 (15.07.99)
(21) International Application Number: PCT/EP98/08330		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 18 December 1998 (18.12.98)		
(30) Priority Data: MI97A002896 30 December 1997 (30.12.97) IT		
(71) Applicant (for all designated States except AU CA GB IE US): BRACCO S.P.A. [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT).		
(71) Applicant (for AU CA GB IE only): DIBRA S.P.A. [IT/IT]; Piazza Velasca, 5, I-20122 Milano (IT).		
(72) Inventors; and (75) Inventors/Applicants (for US only): GEREMIA, Renato [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). MURRU, Marcella [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). RIPA, Giorgio [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). VALLE, Vittorio [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT).		<b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
(74) Agents: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT) et al.		

(54) Title: 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID DERIVATIVES AS CHELATING AGENTS



## (57) Abstract

Compounds of general formula (I), in which R is hydrogen, a straight or branched or cyclic C<sub>1</sub>-C<sub>6</sub> alkyl group, unsubstituted or substituted by 1 to 10 oxygen atoms, or a C<sub>1</sub>-C<sub>20</sub> alkyl group, optionally interrupted by a phenylene, in its turn substituted by a straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl group, unsubstituted or substituted 1 to 3 C<sub>1</sub>-C<sub>7</sub> groups; the aromatic group being unsubstituted or substituted by alkoxy, carboxy, sulfamoyl, hydroxyalkyl, amino groups; as well as their complexes with bi- trivalent metal ions having atomic number variable from 20 to 31, 39, 42, 43, 44, 49, or from 57 to 83, as well as their salts with anions of physiologically acceptable organic acids.


**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon		Republic of Korea	PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

## 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID DERIVATIVES AS CHELATING AGENTS

The present invention relates to the novel 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid derivatives of formula (I), their complexes with paramagnetic metal ions and physiologically compatible salts thereof, as well as to the preparation thereof and the use thereof for the preparation of chelating agents.



In particular the present invention relates to the derivatives of the novel compound, 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid of formula (X), its chelated complex salts with paramagnetic metal ions and the physiologically compatible salts thereof, as well as to the preparation thereof and the use thereof for the preparation of chelating agents.



The compounds of general formula (I), and in particular the compound of formula (X), are novel chelating agents for bi- trivalent metal ions and are

also important intermediates for the synthesis of 1,4,7,10-tetraazacyclododecane derivatives chelating agents, symmetrically functionalized at the 1- and 4-positions.

5       The compounds of general formula (I) are therefore the starting material for the synthesis of multidentate derivatives which are capable of complexing different metals, some of which have applications in the biomedical field, such as gadolinium complexes of said  
10 derivatives, which are used in diagnostic as contrast agents for the magnetic resonance technique (Magnetic Resonance Imaging, MRI).

      In particular, the medical diagnosis by means of "Magnetic Resonance Imaging" (M.R.I.), which is known to  
15 be a powerful diagnostic means in the clinical practice (Stark, D.D., Bradley, W. G., Jr., Eds. "Magnetic Resonance Imaging" The C. V. Mosby Company, St. Louis, Missouri (USA), 1988), mainly makes use of paramagnetic pharmaceutical compositions, preferably containing  
20 chelated complex salts of bi- and trivalent paramagnetic metal ions with aminopolycarboxylic acids and/or derivatives or analogues thereof.

      Presently some of them are used in clinic as M.R.I. contrast agents (Gd-DTPA, N-methylglucamine salt of the  
25 gadolinium complex with diethylenetriaminopentaacetic acid, MAGNEVIST<sup>(R)</sup>, Schering; Gd-DOTA, N-methylglucamine salt of the gadolinium complex with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTAREM<sup>(R)</sup>, Guerbet).


30       A list of significant patent literature for illustrating the prior art in this diagnostic field, although only exemplary and incomplete, is the

3

following: EP 71564 (Schering), US 4639365 (Sherry), US-A-4615879 (Runge), DE-A-3401052 (Schering), EP 130934 (Schering), EP 65728 (Nycomed), EP 230893 (Bracco), US-A-4826673 (Mallinckrodt), US-A-4639365 (Sherry), EP 299795 (Nycomed), EP 258616 (Salutar), WO 8905802 (Bracco).

Object of the present invention are the compounds of general formula (I):

10



15

in which

R is a hydrogen atom, a straight or branched or cyclic C<sub>1</sub>-C<sub>6</sub> alkyl group, unsubstituted or substituted by 1 to 10 oxygen atoms, or a C<sub>1</sub>-C<sub>20</sub> alkyl group, optionally interrupted by a phenylene, in its turn substituted by a straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl group, unsubstituted or substituted by 1 to 3 C<sub>1</sub>-C<sub>7</sub> groups; the aromatic group being unsubstituted or substituted by alkoxy, carboxy, sulfamoyl, hydroxyalkyl, amino groups;

25

as well as their complexes with bi- trivalent metal ions having atomic number variable from 20 to 31, 39, 42, 43, 44, 49, or from 57 to 83, as well as their salts with anions of physiologically acceptable organic acids, selected, for example, from acetate, succinate, citrate, fumarate, maleate, oxalate, or with anions of inorganic acids such as halo acids ions, namely chlorides,

30

bromides, iodides. Metal ions suitable for preparing complex salts with the novel chelating agents of general formula (I) are mainly bivalent or trivalent ions of the elements having atomic number variable from 20 to 31, 39, 42, 43, 44, 49, or from 57 to 83; particularly preferred being  $\text{Fe}^{(2+)}$ ,  $\text{Fe}^{(3+)}$ ,  $\text{Cu}^{(2+)}$ ,  $\text{Cr}^{(3+)}$ ,  $\text{Gd}^{(3+)}$ ,  $\text{Eu}^{(3+)}$ ,  $\text{Dy}^{(3+)}$ ,  $\text{La}^{(3+)}$ ,  $\text{Yb}^{(3+)}$  or  $\text{Mn}^{(2+)}$  or also radioisotopes as  $^{51}\text{Cr}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{111}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{140}\text{La}$ ,  $^{175}\text{Yb}$ ,  $^{153}\text{Sm}$ ,  $^{166}\text{Ho}$ ,  $^{90}\text{Y}$ ,  $^{149}\text{Pm}$ ,  $^{177}\text{Lu}$ ,  $^{47}\text{Sc}$ ,  $^{142}\text{Pr}$ ,  $^{159}\text{Gd}$ ,  $^{212}\text{Bi}$ .

Preferably R can be selected from the group consisting of: H or a straight or branched alkyl group, such as a methyl, ethyl, propyl, isopropyl, butyl, isobutyl group, in its turn substituted by hydroxy groups or interrupted by oxygen atoms, as defined above.

When an aromatic group is present in R, particularly preferred are the phenyl and benzyl groups.

Particularly preferred are the compounds of formula (I) selected from the group consisting of:  $\alpha,\alpha'$ -dimethyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid;  $\alpha,\alpha'$ -diethyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid; and  $\alpha,\alpha'$ -dibenzyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid.

Preferred anions of inorganic acids suitable for salifying the chelated complexes of the invention comprise, in particular, halo acids ions such as chlorides, bromides, iodides or other ions, such as sulfate.

Preferred anions of organic acids suitable for the above aim comprise those of the acids conventionally used in pharmaceutical technique for the salification of

5


basic substances, such as acetate, succinate, citrate, fumarate, maleate.

Preferred amino acids anions comprise, for example, those of taurine, glycine, lysine, arginine or  
5 ornithine, or of aspartic and glutamic acids.

The formation of the complex metal salt is carried out conventionally, preferably in water or in a suitable water-alcohol mixture, by reacting compounds (I) with a metal salt (oxide or halide), whereas the temperature  
10 can range from 25°C to 100°C, preferably from 40°C to 80°C.

The choice of the metal ion and of any neutralizing ion is closely related to the intended use of the complex to be prepared.

15 The preparation of the novel compound, manganese complex of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid, which is in the neutral form and therefore does not require the formation of a physiologically compatible salt, is described in the Experimental  
20 section.



The novel compounds of the present invention have a good tolerability; moreover, their water solubility and the low osmolality of their solutions are a further  
30 advantageous characteristic which makes them particularly suitable for use in nuclear magnetic resonance.

Both soluble and less soluble compounds are useful for the oral and enteral administrations and, therefore, for the imaging of the GI tract.

As far as the parenteral administration is concerned, the compounds are preferably formulated as a sterile aqueous solution or suspension, whose pH can range for instance from 6.0 to 8.5.

These aqueous solutions or suspensions can be administered in concentrations ranging from 0.002 to 1.0 mol.

These formulations can be lyophilized and supplied as they are for reconstitution before use. For the GI use or for the injection in the body cavities, such agents can be formulated as a solution or suspension containing suitable additives, for example thickeners.

In the oral administration they can be formulated according to preparation methods commonly used in the pharmaceutical practice possibly as coated formulations in order to get additional protection from the stomach acid pH, by preventing the release of the chelated metal ion occurring in particular at pH typical of gastric juices.

Other excipients, for instance sweeteners and/or flavouring agents, can also be added according to known techniques of pharmaceutical formulation.

The chelated complex salts of this invention can also be used as radiopharmaceuticals in nuclear medicine, both in the diagnostic and therapeutic sector.


In this case, however, the metal ion which is chelated is a radioisotope, for instance  $^{51}\text{Cr}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{111}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{140}\text{La}$ ,  $^{175}\text{Yb}$ ,  $^{153}\text{Sm}$ ,  $^{166}\text{Ho}$ ,  $^{90}\text{Y}$ ,  $^{149}\text{Pm}$ ,  $^{177}\text{Lu}$ ,  $^{47}\text{Sc}$ ,  $^{142}\text{Pr}$ ,  $^{159}\text{Gd}$  and  $^{212}\text{Bi}$ .



The compounds of the invention can optionally be chemically conjugated with suitable macromolecules or included in suitable carriers.

It is also an object of the invention the process for the preparation of the compounds of general formula (I) starting from triethylenetetramine of formula (II), comprising the following steps represented in Scheme 1:

Scheme 1



- a) condensation of triethylenetetramine of formula (II) with a glyoxal derivative (glyoxal hydrate, or Bertagnini's salt), in water or in water-soluble solvents or in mixtures thereof, at a temperature of 0-50°C, in the presence of a stoichiometric amount or a slight excess of calcium hydroxide to give octahydro-3H,6H-2a,5,6,8a-tetraazacenaphthylene of formula (III);
- b) condensation of the compound from step a) with an alkylating agent  $X-CH_2-CH_2-X$ , in which X is Cl or Br in amounts from 1 to 5 mols per mol of compound (III), in a dipolar aprotic solvent and in the presence of a base selected from alkali or alkaline-earth metal carbonates, in amounts from 5 to 10 mols per mol of compound (III), and with the addition of NaY, wherein Y is I or Br, as catalyst in amounts from 0.1 to 2 mols per mol of compound (III), wherein X and Y are not at the same time Br, at a temperature from 25 to 150°C, to give decahydro-2a,4a,6a,8a-tetraazacyclopent[fg]acenaphthylene of formula (IV);
- c) oxidation of compound (IV) with bromine at pH 4-5 to give 2,3,4,6,7,8-hexahydro-1H,5H-4a,6a-diaza-2a,8a-azoniacyclopent[fg]acenaphthylene dibromide of formula (V);
- d) formation of 2,3,4,6,7,8-hexahydro-1H,5H-4a,6a-diaza-2a,8a-azoniacyclopent[fg]-acenaphthylene diperchlorate of formula (VI), poorly water-soluble, by addition of perchlorate ions to the solution of compound (V);
- e) alkylation of compound of formula (VI) with an alkylating agent of formula  $R-CH(X)COOH$ , in which X

is a halogen, and R is defined as above, in basic conditions, to give the novel compounds of formula (VII);

- 5 f) hydrolysis of the formyl group of compounds (VII) in basic conditions to give the novel compounds of formula (VIII);
- g) alkylation of compound (VIII) with the alkylating agent of formula  $R-CH(X)-COOH$ , in which X and R have the meanings defined above, in basic  
10 conditions, to give the novel compounds of formula (IX);
- h) final hydrolysis of compounds (IX), in basic conditions, to give the compounds of formula (I).

The process of the present invention requires no  
15 isolation of the intermediate compounds, although this has been carried out to correctly identify their structures by means of various analytic techniques.

The process of the invention is particularly useful from the industrial point of view since it allows to  
20 prepare compounds (I) from inexpensive precursors such as triethylenetetramine, instead of expensive macrocyclic derivatives.

Steps a) and b) are object of Italian Patent application MI 97A000783, in the Applicant's name, and  
25 provide compound (IV) in good yields.

In particular, in step b), the alkylating agent is generally added in amounts from 1 to 5 mols per mol of compound (III).

The reaction takes place in dipolar aprotic  
30 solvents, preferably selected from the group consisting of: DMAC (dimethylacetamide), DMF (dimethylformamide), DMSO (dimethylsulfoxide) and N-methyl-pyrrolidone; and

10

in the presence of an inorganic base, preferably an alkali metal carbonate.

The temperature, depending on the solvent and on the alkylating agent, can range from 25 to 150°C, preferably from 30 to 80°C. The reaction time is 1-48 h.

More specifically, when using 1,2-dichloroethane and NaBr, temperature ranges from 50 to 80°C and the reaction time ranges from 2 to 5 h.

When using 1,2-dichloroethane and NaI, temperature ranges from 30 to 50°C and the reaction time ranges from 5 to 15 h.

Step c) is the oxidation with bromine in amounts of 2 - 2.5 mols per mol of compound (IV) in aqueous solution at pH of 4 - 5, obtained by addition of an acid and kept during the reaction by addition of a base, preferably NaOH or KOH.

The reaction temperature ranges from 17 to 30°C and the reaction time is usually 16 hours.

At the end of the reaction, and this is step d) of the present invention, sodium perchlorate or perchloric acid are added in amounts ranging from 2.5 to 3 mols per mol of compound (IV), thereby precipitating compound (VI) in good yields.

The alkylation conditions in step e) are usual in literature.

Particularly preferred are the alkylating agents of formula  $R-CH(X)-COOH$  in which X is bromine or chlorine and most preferred are the alkylating agents of formula  $XCH_2COOH$ , in which R is the hydrogen atom and X is bromine or chlorine.

The alkylation reaction is usually carried out in the following conditions: the reaction temperature can

11

range from 30 to 70°C; the reaction time usually ranges from 10 to 25 hours; basic pH from 10 to 12 is obtained by addition of a base, preferably sodium or potassium hydroxide; the amount of alkylating agent is stoichiometric or in a slight excess ( $1 \div 2$  mols).


Step f) is the hydrolysis of compounds (VII) in aqueous solution at pH made basic by addition of a base, preferably NaOH or KOH, at temperatures ranging from 50 to 100°C.

Step g) is effected as already described for step e).

Step h) is the hydrolysis of compounds (IX) in aqueous solution at pH made basic by addition of 3-7 mols of a base, preferably NaOH or KOH, at temperatures ranging from 150-220°C.

Particularly preferred is the process of the invention for the preparation of compound (X), according to the following Scheme 2:

12

Scheme 2

in which in step e) and g) the alkylating agent is the compound of formula XCH<sub>2</sub>COOH and through formation of the novel intermediate compounds:

· 7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid of formula (VIIa); 1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid of formula (VIIIa); 1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acid of formula (IXa).


The preferred conditions in the presence of BrCH<sub>2</sub>COOH as alkylating agent, are at least 1.5 mols of

13







alkylating agent per mol of starting product and the temperature is 45°C; the reaction time is 21 hours; and pH is 11.5.

Steps e) and g) are carried out using the same alkylating agent, namely  $\text{BrCH}_2\text{COOH}$ , and the same conditions can therefore be used for the two steps.

It is moreover possible to directly alkylate compound (V) or compound (VI) with at least 4 mols of  $\text{XCH}_2\text{COOH}$ , preferably  $\text{BrCH}_2\text{COOH}$ , per mol of starting product, at a temperature of 90°C and at basic pH, thus obtaining compound (IXa), without the step of formation of the intermediates shown above, as represented in the following Scheme:



A further object of the invention are the novel compounds of general formulae (VII), (VIII), and (IX), in which R is defined as above; more particularly those of formulae (VIIa), (VIIIa), and (IXa), in which R is a hydrogen atom






which compounds are useful as intermediates in the process shown in Scheme 1.




Analogously to 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid, the novel chelating agents were prepared:  $\alpha,\alpha'$ -dimethyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid, in which R in formula (I) is methyl;  $\alpha,\alpha'$ -diethyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid, in which R is ethyl;  $\alpha,\alpha'$ -dibenzyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid, in which R is benzyl.

In this case also the process for the preparation of the novel chelated complexes involves novel intermediate compounds, namely:  $\alpha$ -methyl-7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic,  $\alpha$ -methyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic,  $\alpha,\alpha'$ -dimethyl-1,4,7,10-tetraazabicyclo[8.2.1]-tridecane-13-on-4,7-diacetic acids;.








$\alpha$ -ethyl-7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic,  $\alpha$ -ethyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic,  $\alpha, \alpha'$ -diethyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acids;



$\alpha$ -benzyl-7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic,  $\alpha$ -benzyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic,  $\alpha, \alpha'$ -dibenzyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acids.



30 It has also surprisingly been found that the hydrolysis of compounds (VII) and (VIII), and in particular (VIIa) and (VIIIa), in basic conditions (pH


16

>13), obtained by addition of a base, preferably NaOH or KOH, at high temperature (150-220°C, preferably 180-200°C) and under pressure, yields compounds of formula (XI), in which R is defined as above.

5

10


15



Said compounds are useful both as chelating agents for metal ions, and for the preparation of variously substituted chelating agents.

20


The process is particularly preferred for the preparation of the already known compound, 1,4,7,10-tetraazacyclododecane-1-acetic acid (see Meunier et al., Can. J. Chem., 73, 685, 1995), when R is a hydrogen atom.



Also in this case the process for the preparation  
15 of this compound is more efficient and more suited for  
the industrial application than that already described  
in literature.

It is also an object of the invention the process  
for the preparation of compounds (I), comprising the  
20 steps represented in the following Scheme 3:

Scheme 3




19

in which step d) of the above Scheme is omitted and compound (V) is directly alkylated according to the procedure described in step e) of Scheme 1, to give compound (VII).

5 Particularly preferred is the process according to Scheme 3 for the preparation of compound (X), in which R is a hydrogen atom.

The compounds of general formula (I) are in their turn useful substrates for the preparation of compounds  
10 of general formula (XII),




in which

R has the same meanings as defined above;

20  $R_1$  is a hydrogen atom, a straight or branched or cyclic  $C_1$ - $C_6$  alkyl group, unsubstituted or substituted by 1 to 10 oxygen atoms, or a  $C_1$ - $C_{20}$  alkyl group, optionally interrupted by a phenylene, phenyleneoxy or phenylenedioxy in its turn  
25 substituted by a straight or branched  $C_1$ - $C_6$  alkyl group, unsubstituted or substituted by 1 to 7 hydroxy groups or 1 to 3  $C_1$ - $C_7$  groups; the aromatic group being unsubstituted or substituted by alkoxy groups or by halogens, carboxy, carbamoyl,  
30 alkoxy carbonyl, sulfamoyl, hydroxyalkyl, amino, acylamino, acyl, hydroxyacyl;

Z is one of the following groups

20




5

R' independently of R<sub>1</sub>, has the same meanings as R<sub>1</sub> except for the hydrogen atom.

The compounds of formula (XII) are useful as chelating agents of paramagnetic metal ions, for the preparation of contrast agents for NMR diagnostics, as described for example in EP 325762.

Particularly preferred are the compounds of general formula (XIII),


15



20

in which R and R<sub>1</sub> have the meanings defined above.

It is also an object of the present invention the process for the preparation of compounds (XIII), starting from compounds (I) by alkylation, according to known methods, with an excess of an alkylating agent R<sub>1</sub>-CH(X<sub>1</sub>)-COY of formula (XIV), represented in the following Scheme 4:

Scheme 4

10 in which

$R_1$  and  $R$  have the meanings as defined above;

$X_1$  is a halogen or a sulfonic acid reactive residue;

$Y$  is a  $-OH$  or  $-OR_2$  group, wherein  $R_2$  is a

15 straight or branched  $C_1$ - $C_4$  alkyl group;  
when  $Y$  is  $-OR_2$ , the ester groups are  
hydrolysed to obtain compounds of formula  
(XIII).

Alkylating agents of formula (XIV) corresponding to  
20 compound  $R_1-CH(X_1)-COOH$ , in which  $X_1$  is bromine or  
chlorine, are preferred, particularly preferred being  
the alkylating agents of formula  $X_1CH_2COOH$ , in which  $R$   
is the hydrogen atom, and  $X_1$  is bromine or chlorine.

In the other cases the alkylating agent of formula  
25 (XIV) can be selected from the compounds which are  
already commercially available or whose preparation has  
already been described in literature (see for example WO  
93/24469 or EP 325762), or those still to synthesize,  
using for example known methods for the preparation of  
30 suitable precursors (for example, for acyl chloride  $\alpha$ -  
halogen derivatives, see: Harpp et al., J. Org. Chem.,  
40. 3420. 1975), and subsequent transformation into the

desired product.

Preferably  $R_1$  can be selected from the group consisting of: H or a straight or branched alkyl group, such as a methyl, ethyl, propyl, isopropyl, butyl, isobutyl group, in its turn substituted by hydroxy groups or interrupted by oxygen atoms, as defined above.

When an aromatic group is present in  $R_1$ , particularly preferred are the phenyl, benzyl, phenylmethoxymethyl groups.

Particularly preferred are 3-(phenylmethoxy)-propanoic acid reactive derivatives, such as 2-bromo-3-(phenylmethoxy)propanoic acid, the preparation of which is described in Grossman et al., Chem. Ber., 91, 538, 1958, and 2-chloro-3-(phenylmethoxy)propanoic acid (CAS RN 124628-32-6), prepared analogously to the brominated derivative.

On the other hand,  $R_2$  is preferably selected from the group consisting of: methyl, ethyl, isopropyl, butyl, tert-butyl.

The reactive group  $X_1$  can be selected, by way of example, as already mentioned, from the group consisting of halogens (Cl, Br, I), or it can be a mesylate ( $\text{MeSO}_2\text{O}^-$ ), benzenesulfonyloxy ( $\text{PhSO}_2\text{O}^-$ ), nitrobenzenesulfonyloxy ( $p\text{-NO}_2\text{PhSO}_2\text{O}^-$ ), tosylate ( $\text{TsO}^-$ ), or triflate ( $\text{CF}_3\text{SO}_3^-$ ) group.

The alkylation of compounds (I), when Y is the hydroxy group, can conveniently be performed as shown in Scheme 1 above.

Particularly preferred are the alkylating agents of general formula (XIV), in which Y is a hydroxy group, corresponding to bromoacetic acid (commercially available product), 2-bromopropionic acid (commercially



available product), 2-bromobutyric acid (commercially available product).

The reaction solvent can suitably be selected from dipolar aprotic solvents, in particular from  
5 dimethylformamide (DMF), dimethylacetamide (DMA), dimethylsulfoxide (DMSO), acetonitrile ( $\text{CH}_3\text{CN}$ ) and N-methylpyrrolidone, and the reaction is carried out in the presence of an organic base, preferably a tertiary aliphatic amine selected from triethylamine (TEA),  
10 diisopropylethylamine and tributylamine.


In this case it can be convenient to also transform the acid groups present in the compound of formula (I), into the ester group  $-\text{OR}_2$ , in order to promote the alkylation reaction, depending on the reactivity of the  
15 alkylating agent itself.

The reaction temperature will range, in this case, from 0 to  $80^\circ\text{C}$ , depending on the reactivity of the selected alkylating agent.


In this case, the alkylation reaction will be  
20 followed by basic hydrolysis of the resulting diester, in conventional conditions, to obtain the desired compound of general formula (XIII).

By way of example of the huge potentialities provided by this synthetic route, the Experimental  
25 section describes the synthesis of the novel compound,  $\alpha, \alpha'$ -bis(methyl)-1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-tetraacetic acid:


24



as well as that of  $\alpha,\alpha'$ -bis[(phenylmethoxy)methyl]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid



which by catalytic hydrogenation, as described in example 6 of EP 325762, yields  $\alpha,\alpha'$ -bis(hydroxymethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid.




On the other hand, when in compounds (XII) Z is a phosphonic or phosphinic group, said compounds are prepared according to methods known in literature. More specifically, phosphonic derivatives are obtained from hydrochlorides or hydrobromides of the corresponding

25

cyclic amines by reaction with formaldehyde and phosphorous acid ( $\text{H}_3\text{PO}_3$ ) (see Sherry et al., Inorg. Chem., 28, 3336, 1989). The phosphine compounds are obtained from compound (I), previous esterification  
 5 (e.g. formation of the t-butyl ester) by reaction with the corresponding phosphine derivative (such as diethoxymethylphosphine,  $(\text{EtO})_2\text{PMe}$ ) and paraformaldehyde, in anhydrous solvents. The resulting diester from the condensation is hydrolysed in acid solution at  
 10 high temperature, to obtain the corresponding alkylphosphinic acid (see, e.g. Parker et al., J. Chem.Soc. Chem. Commun., 1738, 1990).

The synthesis of the novel compound, 1,4,7,10-tetraazacyclododecane-1,4-diacetic-7,10-dimethylenedi-  
 15 phosphonic acid of formula (XV), starting from compound (I), according to methods known in literature, is reported in the Experimental section.

20




25

In the following, some preparation examples according to the method of the present invention are reported.

### Experimental section

#### EXAMPLE 1

2,3,4,6,7,8-Hexahydro-1H,5H-4a,6a-diaza-2a,8a-azoniacyclopent[fg]acenaphthylene diperchlorate



A) Triethylenetetramine hydrate


520 g of commercial triethylenetetramine (starting purity 62%, GC in % area) are dissolved in 800 mL of toluene. 80 mL of water are added under stirring, the mixture is cooled at 25°C and seeded with purified triethylenetetramine. The suspension is stirred for 45 min. at 20°C, then cooled at 5-10°C for 1h. The crystallized solid is filtered, washed with some toluene, then dried at 30°C under vacuum for 8h. 365 g of desired product are obtained.

Yield: 91% on theoretical

Water content: 17%

GC: 97% (in % area)

B) 3H,6H-2a,5,6,8a-Octahydro-tetraazacenaphthylene



A solution of triethylenetetramine hydrate (100 g, 0.54 mol) in water (1 L) is added with 80 g (1.08 mol) of calcium hydroxide. The milky suspension is cooled to a temperature of 5°C, then added with a 5% glyoxal aqueous solution (626 g, 0.54 mol) under stirring. After 2 h the reaction is completed (absence of triethylenetetramine, GC analysis). After warming at a temperature of 20°C, the insoluble inorganic solid is filtered off and

27

washed with water. The filtrate is concentrated to dryness under vacuum in rotating evaporator.


100 g of the desired intermediate in the form of a colourless oily liquid are obtained. (GC purity: >75%)

5 Yield: 70%.

$^1\text{H}$ -NMR,  $^{13}\text{C}$ -NMR, IR and MS spectra are consistent with the indicated structure.

C) 2a,4a,6a,8a-Decahydro-tetraazacyclopent[fg]acena-  
phthylene

10



15 266 g (1.58 mol) of 3H,6H-2a,5,6,8a-octahydro-tetraazacenaphthylene are added with 4.4 L of dimethylacetamide, 837 g of  $\text{Na}_2\text{CO}_3$  (7.9 mol) and 81.3 g of NaBr (0.79 mol). The suspension is heated to 58°C, then 469 g of 1,2-dichloroethane (4.74 mol) dissolved in  
20 800 mL of DMAC are added under stirring. The mixture is heated to 80°C and reacted for 3h. The suspension is cooled, salts are filtered off, the filtrate is added with 192 g of celite and the solvent is distilled off under reduced pressure. The residue is taken up with  
25 hexane and 4 solid-liquid extractions are performed. The organic extracts are concentrated to dryness to obtain 184 g of the desired product (0.94 mol).

Yield 59%

GC: 98.5% (in % area)

30  $^1\text{H}$ -NMR,  $^{13}\text{C}$ -NMR, IR and MS spectra are consistent with the indicated structure.

D) 2,3,4,6,7,8-Hexahydro-1H,5H-4a,6a-diaza-2a,8a-

28

azoniacyclopent[fg]acenaphthylene diperchlorate

50.4 g (0.259 mol) of 2a,4a,6a,8a-decahydro-tetraazacyclopent[fg]acenaphthylene are dissolved in 955 g of demineralized water. 290 g of 1N HCl are added to pH 4.5, then the solution is cooled at 20°C and 104.93 g (0.65 mol) of bromine and, at the same time, 1.256 kg of 1N NaOH, are dropped therein to keep pH at 4.5. The mixture is reacted overnight at room temperature, the solution is concentrated under reduced pressure and at 50°C to a weight of 0.73 kg, then cooled to 25°C and added with 146 g of a 50% w/w aqueous solution of sodium perchlorate monohydrate, under stirring. After 2 h the precipitate is filtered and washed with water. After drying in static drier under vacuum at 50°C, 61.34 g (0.156 mol) of product are obtained.

Yield: 60%.

Electrophoretic method


Capillary:	fused silica 0.56 m x 75 mm
Voltage:	12kV
20 Buffer	0.05 M phosphate pH 4.5
Temperature:	40°C
Stoptime:	20 min.
Detection: (UV)	200-220 nm
Injection:	hydrostatic (50 mbar, 3s)
25 Sample conc.:	1mg/mL
Instrumentation:	Hewlett Packard 3D HPCE
Preconditioning timetable:	t (min)                      action
	0                      washing with H <sub>2</sub> O
	2                      washing with 0.1 M NaOH
30	4                      washing with H <sub>2</sub> O
	5                      washing with buffer
	9                      start analysis

29

## EXAMPLE 2

Synthesis of 7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid

5



10            20 g (0.051 mol) of compound (VI) prepared in Example 1 are suspended in 200 mL of demineralized water. 2N NaOH is added to reach pH 12 and the mixture is heated at 45°C. A 80% w/w bromoacetic acid aqueous solution (19.5 g, 0.11 mol) and 2N NaOH are dropped  
15 simultaneously to keep pH 12. The mixture is reacted for 5 h at 45°C. The solution is cooled and acidified to pH 1.1 with 34% w/w HCl. The suspension is stirred for 3 hours at 22°C and filtered by suction, washing the solid on the filter with demineralized water. After drying in  
20 static drier under vacuum, 18.67 g (0.048 mol) of the desired product are obtained, which is isolated as perchlorate.

Yield: 94%

25            <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, IR and MS spectra are consistent with the indicated structure.

Analogously are prepared:


α-methyl-7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid;  
α-ethyl-7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid;  
30 α-benzyl-7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-4-acetic acid.

30

## EXAMPLE 3

Synthesis of 1,4,7,10-tetraazabicyclo[8.2.1]tridecane-  
13-on-4-acetic acid

5



10        10 g (0.026 mol) of compound (VIIa) prepared in  
Example 2, are suspended in 100 mL of demineralized  
water. 2N NaOH is added to pH 12 and the mixture is  
heated at 90°C for 5 hours keeping the desired pH by  
addition of 2N NaOH. The solution is cooled at 22°C and  
15        adjusted to pH 1.1 by acidification with 34% HCl (w/w).  
The solution is partially concentrated in rotating  
evaporator and the inorganic precipitate is filtered.  
The solution is percolated on 0.38 L of polystyrene  
adsorbing resin XAD-1600 eluting with demineralized  
20        water. The fractions containing the product free from  
chloride ions are collected, combined and concentrated  
to a residue in rotating evaporator.

5.35 g (0.015 mol) of the desired product are  
obtained as the perchlorate.

25        Yield: 57 %

$^1\text{H}$ -NMR,  $^{13}\text{C}$ -NMR, IR and MS spectra are consistent with  
the indicated structure.

Analogously are prepared:

30         $\alpha$ -methyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-  
4-acetic acid;  
 $\alpha$ -ethyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-  
4-acetic acid;




31

$\alpha$ -benzyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid.

**EXAMPLE 4**

Synthesis of 1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acid



20 g (0.051 mol) of compound (VI) prepared in Example 1 are suspended in 200 ml of demineralized water. 35% NaOH (w/w) is added to pH 11.5, while dropping 22.06 g (0.127 mol) of a 80% (w/w) bromoacetic acid aqueous solution and 2N NaOH to keep pH 11.5 during the addition, in four hours, heating to a temperature of 90°C. At the end of the addition the reaction is completed keeping the solution at 45°C for a further 3 hours. The solution is acidified with a 34% HCl solution (w/w) to pH 1.1 and percolated on a column containing 2.2 L of adsorbing resin XAD-1600. The fractions containing the product purified and free from inorganic salts are collected and concentrated to a solid residue.

13.2 g (0.042 mol) of the desired product are obtained.

Yield: 82 %

$^1\text{H}$ -NMR,  $^{13}\text{C}$ -NMR, IR and MS spectra are consistent with the indicated structure.

Analogously are prepared:

$\alpha,\alpha'$ -dimethyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acid;

32

$\alpha, \alpha'$ -diethyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acid;

$\alpha, \alpha'$ -dibenzyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acid.

5

**EXAMPLE 5**

Alternative to Example 4 without recovery of compound (VI)

29.1 g (0.15 mol) of compound (IV) prepared in Example 1 are dissolved in 570 g of demineralized water.  
10 174 g of 1N HCl are added reach to pH 4.5, then the solution is cooled at 20°C and 60 g (0.375 mol) of bromine and 0.75 kg of 1N NaOH are dropped therein simultaneously, to keep pH at 4.5. After reacting overnight at room temperature, the solution is  
15 concentrated to 200 g under reduced pressure and at 50°C. The resulting solution is added dropwise with 104.3 g (0.6 mol) of 80 % w/w bromoacetic acid solution at 90°C during 5 hours, keeping pH 11.5. The resulting solution is kept at this pH and at this temperature for  
20 5 hours, to obtain a solution that is cooled to 23°C and acidified to pH 1.1 with a 34 % w/w HCl solution. After partial concentration to 530 g, the solution is percolated on a column containing 4.2 L of polystyrene adsorbing resin XAD-1600, eluting with demineralized  
25 water and collecting the fractions containing the product useful and free from salts, which are combined and concentrated to a solid residue.

33 g (0.105 mol) of 1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acid are  
30 obtained.


Yield: 70 %

33

## EXAMPLE 6

Synthesis of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid

5



10 11.63 g (0.037 mol) of compound (IXa) prepared in Example 4 are suspended in a solution containing 50 mL of demineralized water and 24.9 g of 30% w/w NaOH. The resulting solution is placed in autoclave Parr and heated at 195°C for 22 hours, then acidified to pH 4 by  
15 adding dropwise 20 g of a solution of 34% w/w HCl and filtered through paper. The resulting solution is purified on a strongly anionic ion-exchange resin and on polyvinylpyridine resin and the product is recovered by crystallization from a methanol/acetone solution.

20 6.34 g (0.022 mol) of the desired product are obtained.

Yield: 60 %

$^1\text{H}$ -NMR,  $^{13}\text{C}$ -NMR, IR and MS spectra are consistent with the indicated structure.


25 Analogously are prepared:

$\alpha,\alpha'$ -dimethyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid;

$\alpha,\alpha'$ -diethyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid;

30  $\alpha,\alpha'$ -dibenzyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid.

34  
EXAMPLE 7



15 g (0.038 mol) of compound (VIIa) prepared in Example 2 are suspended in 50 mL of demineralized water and 25.3 g of 30% w/w NaOH. The suspension is placed in autoclave Parr and heated at 195°C for 16 hours. The resulting solution is purified on a strongly anionic ion-exchange resin, on a polyvinylpyridine resin and on adsorbing resin XAD-1600. The obtained fractions, containing the purified product, are combined and concentrated to a solid residue.


5.1 g (0.022 mol) of the desired product are thereby obtained.

Yield: 58%

<sup>1</sup>H-NMR, <sup>13</sup>C-NMR, IR and MS spectra are consistent with the indicated structure.

EXAMPLE 8

Synthesis of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid-7,10-dimethylenediphosphonic acid



5.8 g (0.02 mol) of compound (X) obtained in Example 6 are added to 60 mL of 15% w/w HCl and H<sub>3</sub>PO<sub>3</sub>

35


(4.1 g, 0.05 mol). The solution is heated to reflux, then 5.94 ml of a 37% w/w formaldehyde solution (0.08 mol) are dropped therein in 30 minutes. The solution is refluxed for 5 hours, then concentrated to an oily residue. The product is purified by crystallization from water, then dried thereby obtaining 4.8 g (0.01 mol) of the desired product.

Yield: 50%

$^1\text{H}$ -NMR,  $^{13}\text{C}$ -NMR, IR and MS spectra are consistent with the indicated structure

#### EXAMPLE 9

Synthesis of  $\alpha,\alpha'$ -bis(methyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid



5 g (0.017 mol) of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid, prepared according to Example 6, are diluted with 45 g of water and slowly added with a solution prepared dissolving 8.04 g (0.051 mol) of 2-bromopropionic acid in 40 mL of water. The mixture is reacted at 45°C for 12 h, keeping pH at 10.5-11 by addition of 2N NaOH, cooled at room temperature and acidified to pH 2 with conc. with hydrochloric acid. After 1h the precipitated solid is filtered, and the filter is washed with demineralized water. The crude product is redissolved in 600 mL of polyvinylpyridine resin (PVP), eluting repeatedly with water. The useful

36


fractions are combined, concentrated to dryness under vacuum and dried in static drier at 50°C under vacuum, thereby obtaining 5.7 g (0.013 mol) of the desired product.

5 Yield: 76%

$^1\text{H}$ -NMR,  $^{13}\text{C}$ -NMR, IR and MS spectra are consistent with the indicated structure.

#### EXAMPLE 10

Synthesis of  $\alpha, \alpha'$ -bis[(phenylmethoxy)methyl]-  
10 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid



1,4,7,10-Tetraazacyclododecane-1,4-diacetic acid is reacted with 2-bromo-3-(phenylmethoxy)propanoic acid methyl ester or with 2-trifluoromethanesulfonate-2-(phenylmethoxy)-propanoic acid methyl ester in DMF and in the presence of triethylamine. The methyl ester is hydrolysed to obtain the desired product.


25  $^1\text{H}$ -NMR,  $^{13}\text{C}$ -NMR, IR and MS spectra are consistent with the indicated structure.

30

#### EXAMPLE 11

Synthesis of  $\alpha, \alpha'$ -bis(hydroxymethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid

37



5


The product obtained in Example 10 is subjected to catalytic hydrogenation in the presence of 5% Pd/C, to obtain, after adsorption of the necessary hydrogen, the desired product.

$^1\text{H-NMR}$ ,  $^{13}\text{C-NMR}$ , IR and MS spectra are consistent with the indicated structure.

#### EXAMPLE 12

Preparation of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid manganese complex

20



8.66 g of compound (X) prepared as described in Example 6 (30 mmol) are dissolved in 30 mL of water. pH is adjusted to 6.8 by addition of a solution of 1-deoxy-1-(methylamino)-D-glucitol (0.3 mL; 0.3 mmol); after that  $\text{MnCl}_2$  (30 mL; 30 mmol) is added during two hours, maintaining pH 6.8 by addition of 1-deoxy-1-(methylamino)-D-glucitol (28.2 mL; 28.2 mmol). After 24 h the solution is filtered through a Millipore<sup>(R)</sup> filter (HA-0.22 mm), nanofiltered, evaporated and the residue

38

is dried on  $P_2O_5$  to give the desired product (5.0 g; 14.65 mmol). The permeate containing the desired product is concentrated to 50 mL and the resulting solid (meglumine chloride) is filtered and removed. The  
5 solution is evaporated to a residue, that is crystallized from MeOH (50 mL) to yield 3 g of a second crop of the desired product (8.0 mmol).


Yield: 76%

$^1H$ -NMR,  $^{13}C$ -NMR, IR and MS spectra are consistent with  
10 the indicated structure.



CLAIMS

1. Compounds of general formula (I),



in which

R is a hydrogen atom, a straight or branched or cyclic  $C_1-C_6$  alkyl group, unsubstituted or substituted by 1 to 10 oxygen atoms, or a  $C_1-C_{20}$  alkyl group, optionally interrupted by a phenylene, in its turn substituted by a straight or branched  $C_1-C_6$  alkyl group, unsubstituted or substituted by 1 to 3  $C_1-C_7$  groups; the aromatic group being unsubstituted or substituted by alkoxy, carboxy, sulfamoyl, hydroxyalkyl, amino groups; as well as their complexes with bi- trivalent metal ions having atomic number variable from 20 to 31, 39, 42, 43, 44, 49, or from 57 to 83, as well as their salts with anions of physiologically acceptable organic acids.

2. Complexes of compounds of formula (I), as claimed in claim 1, with the metal ions selected from the group consisting of:  $Fe^{(2+)}$ ,  $Fe^{(3+)}$ ,  $Cu^{(2+)}$ ,  $Cr^{(3+)}$ ,  $Gd^{(3+)}$ ,  $Eu^{(3+)}$ ,  $Dy^{(3+)}$ ,  $La^{(3+)}$ ,  $Yb^{(3+)}$  or  $Mn^{(2+)}$ .

3. Compounds of formula (I), as claimed in claim 1, in which R is selected from the group consisting of: H or a

straight or branched alkyl group, such as a methyl, ethyl, propyl, isopropyl, butyl, isobutyl group, in its turn substituted by hydroxy groups or interrupted by oxygen atoms; or, when an aromatic group is present in R, R is selected from phenyl and benzyl.


4. Compounds of formula (I), as claimed in claim 3, selected from the group consisting of: 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid;  $\alpha,\alpha'$ -dimethyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid;  $\alpha,\alpha'$ -diethyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid;  $\alpha,\alpha'$ -dibenzyl-1,4,7,10-tetraazacyclododecane-1,4-diacetic acid.

5. 1,4,7,10-Tetraazacyclododecane-1,4-diacetic acid, as claimed in claim 4.

6. Salts of the complexes of compounds of formula (I), as claimed in claim 1, in which the physiologically compatible anions are selected from the group consisting of: for the inorganic, the ions of the halo acids such as chlorides, bromides, iodides, sulfate; for the organic, acetate, succinate, citrate, fumarate, maleate or the anions of the amino acids: taurine, glycine, lysine, arginine, ornithine or of the aspartic and glutamic acids.

7. Manganese complex of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid, according to claims 1-5.

8. A process for the preparation of compounds of formula (I) starting from triethylenetetramine of formula (II), comprising the steps represented in Scheme 1:

Scheme 1

42

- a) condensation of triethylenetetramine of formula (II) with a glyoxal derivative (glyoxal hydrate, or Bertagnini's salt), in water or in water-soluble solvents or in mixtures thereof, at a temperature of 0-50°C, in the presence of a stoichiometric amount or a slight excess of calcium hydroxide to give octahydro-3H,6H-2a,5,6,8a-tetraazacenaphthylene of formula (III);
- b) condensation of the compound from step a) with an alkylating agent  $X-CH_2-CH_2-X$ , in which X is Cl or Br in amounts from 1 to 5 mols per mol of compound (III), in a dipolar aprotic solvent and in the presence of a base selected from alkali or alkaline-earth metal carbonates, in amounts from 5 to 10 mols per mol of compound (III), and with the addition of NaY, wherein Y is I or Br, as catalyst in amounts from 0.1 to 2 mols per mol of compound (III), wherein X and Y are not at the same time Br, at a temperature from 25 to 150°C, to give decahydro-2a,4a,6a,8a-tetraazacyclo-pent[fg]acenaphthylene of formula (IV);
- c) oxidation of compound (IV) with bromine at pH 4-5 to give 2,3,4,6,7,8-hexahydro-1H,5H-4a,6a-diaza-2a,8a-azoniacyclopent[fg]acenaphthylene dibromide of formula (V);
- d) formation of 2,3,4,6,7,8-hexahydro-1H,5H-4a,6a-diaza-2a,8a-azoniacyclopent[fg]-acenaphthylene diperchlorate of formula (VI), poorly water-soluble, by addition of perchlorate ions to the solution of compound (V);
- e) alkylation of compound (VI) with an alkylating agent of formula  $R-CH(X)COOH$ , in which X is a

halogen, and R is defined as above, in basic conditions, to give the novel compounds of formula (VII);

5 f) hydrolysis of the formyl group of the compounds (VII) in basic conditions to give the novel compounds of formula (VIII);

g) alkylation of compound (VIII) with the alkylating agent of formula  $R-CH(X)-COOH$ , in which X and R have the meanings defined above, in basic  
10 conditions, to give the novel compounds of formula (IX);

h) final hydrolysis of compounds (IX), in basic conditions, to give the compounds of formula (I).

9. A process as claimed in claim 8, in which in step  
15 b) the alkylating agent is added in amounts from 1 to 5 mols per mol of compound (II), at temperatures from 30 to 80°C;

in step c) the oxidation is carried out adding bromine in amounts of 2 - 2.5 mols per mol of compound (IV), in  
20 aqueous solution at pH 4 - 5, at temperatures from 17 to 30°C;

in step d) sodium perchlorate or perchloric acid are added in amounts of 2.5 - 3 mols per mol of compound (IV);.

25 in step e) the reaction temperature ranges from 30 to 70°C, pH ranges from 10 to 12 and is obtained by addition of a base; the amount of alkylating agent is stoichiometric or in excess;

step f) is the hydrolysis of compounds (VII) in aqueous  
30 solution at basic pH, at temperatures from 50 to 100°C;

step g) is effected as already described for step e);

step h) is the hydrolysis of compounds of formula (IX)

in aqueous solution at basic pH, obtained by addition of 3 - 7 mols of a base, at temperatures of 150-220°C.


10. A process according to claims 8 - 9, in which, in the alkylating agent of formula  $R-CH(X)-COOH$ , X is  
5 bromine or chlorine.

11. A process for the preparation of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid (X), as claimed in claim 8, in which in steps e) and g) the alkylating agent of formula  $R-CH(X)-COOH$  is the compound of formula  
10  $XCH_2COOH$  and X is chlorine or bromine.

12. A process as claimed in claim 11, in which the alkylating agent in steps e) and g) is  $BrCH_2COOH$ , added in amounts of at least 1.5 mols of alkylating agent per mol of starting product, at temperatures of 45°C and at  
15 pH 11.5.

13. A process for the preparation of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid (X), as claimed in claim 8, in which steps e), f) and g) are replaced by a single step in which compound (V), or compound (VI),  
20 is reacted with at least 4 mols of  $BrCH_2COOH$ , at a temperature of 90°C and at basic pH.

14. Compound of formula (VII), as intermediate in the process according to claims 8 - 12.




30 15. 7-Formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid of formula (VIIa), as claimed in claim 14, in which R is hydrogen, as intermediate in the

45

preparation of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid.

5



10

16. A compound as claimed in claim 14, selected from the group consisting of:

$\alpha$ -methyl-7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid in which R is the methyl group;


$\alpha$ -ethyl-7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid in which R is the ethyl group;

15

$\alpha$ -benzyl-7-formyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid in which R is the benzyl group.


17. A compound of general formula (VIII), as intermediate in the process according to claims 8 - 12.

20



25

18. 1,4,7,10-Tetraazabicyclo[8.2.1]tridecane-13-on-4-acetic acid of formula (VIIIa), as claimed in claim 17, in which R is a hydrogen atom, as intermediate in the process for the preparation of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid.



19. A compound as claimed in claim 17, selected from the group consisting of:

$\alpha$ -methyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-

4-acetic acid, in which R is the methyl group;


$\alpha$ -ethyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-

4-acetic acid, in which R is the ethyl group;


$\alpha$ -benzyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-

4-acetic acid, in which R is the benzyl group.

20. A compound of formula (IX), as intermediate in the process according to claims 8 - 12.



21. 1,4,7,10-Tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acid of formula (IXa), as claimed in claim 20, in which R is a hydrogen atom, as intermediate in the process for the preparation of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid.



(IXa)




22. A compound as claimed in claim 20, selected from the group consisting of:

$\alpha,\alpha'$ -dimethyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acid, in which R is the methyl group;


5  $\alpha,\alpha'$ -diethyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acid, in which R is the ethyl group;

$\alpha,\alpha'$ -dibenzyl-1,4,7,10-tetraazabicyclo[8.2.1]tridecane-13-on-4,7-diacetic acid, in which R is the benzyl group.

23. A process for the preparation of compounds of formula (XI) starting from compounds of formulae (VII) and (VIII), by hydrolysis in basic conditions at high temperature and under pressure.




25 24. A process for the preparation of 1,4,7,10-tetraazacyclododecane-1-acetic acid, as claimed in claim 23, starting from compound (VIIa) or (VIIIa), by basic hydrolysis under pressure at temperatures of 180-200°C .



25. A process for the preparation of compounds of  
15 formula (I), comprising the steps represented in the  
following Scheme 3:

Scheme 3




50

in which step d) of the process as claimed in claim 8 is omitted and compound (V) is directly alkylated according to the procedure described in step e) of the same claim, to give compound (VII).

26. A process as claimed in claim 25, for the preparation of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid, in which R is a hydrogen atom.

27. A process for preparation of compounds (XIII) starting from compounds (I) by alkylation with an excess of an alkylating agent  $R_1\text{-CH(X}_1\text{)-COY}$  of formula (XIV), represented in the following Scheme 4:

Scheme 4

in which

$R_1$  and R have the meanings as defined above;  
 $X_1$  is a halogen or a sulfonic acid reactive residue;  
Y is a -OH, or -OR<sub>2</sub> group, wherein  
 $R_2$  is a straight or branched C<sub>1</sub>-C<sub>4</sub> group alkyl; when Y is -OR<sub>2</sub>, the ester groups are hydrolysed to obtain compounds of formula (XIII).

28. A process as claimed in claim 27, in which the alkylating agent of formula (XIV) is a compound of formula  $R_1\text{-CH(X}_1\text{)-COOH}$ , in which  $X_1$  is bromine or chlorine and  $R_1$  is selected from the group consisting

51

of: H or a straight or branched alkyl group, such as a methyl, ethyl, propyl, isopropyl, butyl, isobutyl in its turn substituted by hydroxy groups or interrupted by oxygen atoms.


5 29. A process as claimed in claim 28, in which the alkylating agent of formula (XIV) is a compound of formula  $X_1CH_2COOH$ , in which  $R_1$  is hydrogen and  $X_1$  is bromine or chlorine.

10 30. A process as claimed in claim 29, in which the alkylating agent of formula (XIV) is a compound of formula  $X_1CH_2COOH$  and is selected from the group consisting of: bromoacetic acid, 2-bromopropionic acid, 2-bromobutyric acid.

15 31. A process as claimed in claim 27, in which, in the alkylating agent of formula (XIV),  $R_1$  is selected from the group consisting of: phenyl, benzyl, phenylmethoxymethyl;  $X_1$  is selected from the group consisting of: mesylate, benzenesulfonyloxy, nitrobenzenesulfonyloxy, tosylate, triflate;  $R_2$  is  
20 selected from the group consisting of: methyl, ethyl, isopropyl, butyl, tert-butyl.

32. A process according to claims 30 and 31, for the preparation of  $\alpha,\alpha'$ -bis(methyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid and of  $\alpha,\alpha'$ -  
25 bis[(phenylmethoxy)methyl]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid.

33. 1,4,7,10-Tetraazacyclododecane-1,4-diacetic-7,10-dimethylenediphosphonic acid of formula (XV), starting from compound of formula (I) by reaction with  
30 formaldehyde and phosphorous acid ( $H_3PO_3$ ).



34. The use of compounds (VII), (VIII) and (IX) as intermediates for the preparation of compounds of general formula (I).


10 35. A contrastographic diagnostic pharmaceutical composition comprising at least one of the chelated complexes according to claims 1 to 7 or a salt thereof.

36. Pharmaceutical composition as claimed in claim 35, to obtain images of organs and/or tissues of the human or animal body, by the use of the nuclear magnetic resonance.

15 37. The use of the chelated complexes of the compounds of formula (I) or the salts thereof for the preparation of diagnostic formulations, with the aim to obtain images of organs and/or tissues of human and animal bodies, by the application of nuclear magnetic resonance.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 257/02, A61K 49/00, G01N 24/08, C07F 9/38</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/35133</b> <b>(43) International Publication Date:</b> 15 July 1999 (15.07.99)
<b>(21) International Application Number:</b> PCT/EP98/08330 <b>(22) International Filing Date:</b> 18 December 1998 (18.12.98) <b>(30) Priority Data:</b> MI97A002896 30 December 1997 (30.12.97) IT <b>(71) Applicant (for all designated States except AU CA GB IE US):</b> BRACCO S.P.A. [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). <b>(71) Applicant (for AU CA GB IE only):</b> DIBRA S.P.A. [IT/IT]; Piazza Velasca, 5, I-20122 Milano (IT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GEREMIA, Renato [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). MURRU, Marcella [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). RIPA, Giorgio [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). VALLE, Vittorio [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT). <b>(74) Agents:</b> MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT) et al.		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <b>(88) Date of publication of the international search report:</b> 26 August 1999 (26.08.99)
<b>(54) Title:</b> 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID DERIVATIVES AS CHELATING AGENTS <div style="text-align: center;">  </div> <b>(57) Abstract</b> <p>Compounds of general formula (I), in which R is hydrogen, a straight or branched or cyclic C<sub>1</sub>-C<sub>6</sub> alkyl group, unsubstituted or substituted by 1 to 10 oxygen atoms, or a C<sub>1</sub>-C<sub>20</sub> alkyl group, optionally interrupted by a phenylene, in its turn substituted by a straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl group, unsubstituted or substituted 1 to 3 C<sub>1</sub>-C<sub>7</sub> groups; the aromatic group being unsubstituted or substituted by alkoxy, carboxy, sulfamoyl, hydroxyalkyl, amino groups; as well as their complexes with bi- trivalent metal ions having atomic number variable from 20 to 31, 39, 42, 43, 44, 49, or from 57 to 83, as well as their salts with anions of physiologically acceptable organic acids.</p>		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/08330

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D257/02 A61K49/00 G01N24/08 C07F9/38

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K G01N C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 05118 A (CONCAT LTD) 23 February 1995 see page 11; example C ---	33
E	WO 99 05128 A (DIBRA SPA ;UBERTI FULVIO (IT); BELTRAMI ANDREA (IT); BRACCO SPA (I) 4 February 1999 Compounds (II) and (I). see claim 1 ---	1,27
E	WO 99 05145 A (DIBRA SPA ;ARGESE MARIA (IT); BRACCO SPA (IT); RIPA GIORGIO (IT)) 4 February 1999 Compounds (V). see claim 7 --- -/--	1-22,25, 26



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\* document member of the same patent family

Date of the actual completion of the international search

14 April 1999

Date of mailing of the international search report

02.07.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

GETTINS M.P.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/08330

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	EP 0 872 479 A (DIBRA SPA ;BRACCO SPA (IT)) 21 October 1998 see claim 1 ---	1-22,25, 26
Y	WO 95 09161 A (BRACCO INT BV) 6 April 1995 see claim 1 ---	1-22,25, 26
Y	EP 0 545 511 A (SCHERING AG) 9 June 1993 Compounds (I). see page 1, line 1 - line 28 ---	1-22,25, 26
Y	EP 0 481 420 A (NIHON MEDIPHYSICS CO LTD) 22 April 1992 see claim 1 ---	1-22, 25-27
Y	EP 0 448 191 A (SCHERING AG) 25 September 1991 see claim 1 ---	1-22,25, 26
Y	WO 89 05802 A (BRACCO IND CHIMICA SPA) 29 June 1989 cited in the application see claim 1 ---	1-22,25, 26
Y	EP 0 299 795 A (NYCOMED AS) 18 January 1989 cited in the application Compounds (Ie). see claim 1 ---	1-22, 25-27
A	FR 2 736 051 A (GUERBET SA) 3 January 1997 see claim 1 -----	27

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 98/08330

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1 - 22, 25 - 37

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest
- ☐ No protest accompanied the payment of additional search fees

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

1. Claims: 1-22,25-37

Claims for the compounds of formula (I), (VII), (VIII), (IX), (XIII) and (XV).

2. Claims: 23,24

Claims relating to the production of the known compounds (XI).

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/08330

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505118 A	23-02-1995	US 5409689 A AU 7374194 A EP 0717639 A JP 9501919 T	25-04-1995 14-03-1995 26-06-1996 25-02-1997
WO 9905128 A	04-02-1999	IT MI971765 A AU 8631698 A	25-01-1999 16-02-1999
WO 9905145 A	04-02-1999	IT MI971766 A AU 8974298 A	25-01-1999 16-02-1999
EP 0872479 A	21-10-1998	IT MI970930 A JP 11021279 A	19-10-1998 26-01-1999
WO 9509161 A	06-04-1995	US 5358704 A AU 7623494 A CA 2150452 A CN 1115180 A CZ 9501369 A EP 0670832 A JP 8503967 T NO 952111 A	25-10-1994 18-04-1995 06-04-1995 17-01-1996 13-12-1995 13-09-1995 30-04-1996 29-05-1995
EP 0545511 A	09-06-1993	DE 4140779 A CA 2084582 A HU 65526 A IL 103996 A JP 5279349 A NO 303496 B NO 973578 A NO 973579 A NO 973580 A NO 973581 A US 5410043 A	09-06-1993 07-06-1993 28-06-1994 08-02-1998 26-10-1993 20-07-1998 07-06-1993 07-06-1993 07-06-1993 07-06-1993 25-04-1995
EP 0481420 A	22-04-1992	JP 4154729 A AT 133339 T AU 647188 B AU 8591291 A CA 2053478 A DE 69116637 D DE 69116637 T DK 481420 T ES 2085396 T US 5811077 A	27-05-1992 15-02-1996 17-03-1994 30-04-1992 17-04-1992 07-03-1996 30-05-1996 12-02-1996 01-06-1996 22-09-1998
EP 0448191 A	25-09-1991	DE 4009119 A AT 124405 T AU 647091 B AU 7361091 A CA 2038493 A DE 59105815 D DK 448191 T ES 2074219 T FI 911330 A HK 1002811 A HU 215964 B IE 67643 B	26-09-1991 15-07-1995 17-03-1994 19-09-1991 20-09-1991 03-08-1995 20-11-1995 01-09-1995 20-09-1991 18-09-1998 29-03-1999 17-04-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/08330

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0448191	A	IL 97592 A	31-10-1995
		JP 5320146 A	03-12-1993
		NO 179610 B	05-08-1996
		NZ 237461 A	23-12-1993
		PT 97065 A,B	31-10-1991
-----			
WO 8905802	A	29-06-1989	
		AT 120191 T	15-04-1995
		AU 2904789 A	19-07-1989
		DE 3853415 D	27-04-1995
		DE 3853415 T	31-08-1995
		EP 0325762 A	02-08-1989
		EP 0440606 A	14-08-1991
		ES 2070845 T	16-06-1995
		IE 67551 B	17-04-1996
		IL 88762 A	31-07-1995
		JP 2744920 B	28-04-1998
		JP 3501848 T	25-04-1991
		MX 9203262 A	01-07-1992
		PH 26255 A	01-04-1992
		RU 2059642 C	10-05-1996
		US 5132409 A	21-07-1992
-----			
EP 0299795	A	18-01-1989	
		AT 73761 T	15-04-1992
		AT 137228 T	15-05-1996
		AU 1998088 A	13-02-1989
		AU 640263 B	19-08-1993
		AU 8343191 A	07-11-1991
		DE 3855239 D	30-05-1996
		DE 3855239 T	31-10-1996
		DE 3869251 A	23-04-1992
		DK 7490 A	11-01-1990
		EP 0466200 A	15-01-1992
		ES 2086445 T	01-07-1996
		WO 8900557 A	26-01-1989
		GR 3004713 T	28-04-1993
		GR 3020041 T	31-08-1996
		HK 1003572 A	30-10-1998
		HU 208947 B	28-02-1994
		HU 64950 A	28-03-1994
		IE 61746 B	30-11-1994
		IE 71186 B	29-01-1997
		JP 2504269 T	06-12-1990
		JP 2833766 B	09-12-1998
		NO 179973 B	14-10-1996
		RU 2073005 C	10-02-1997
		US 5419893 A	30-05-1995
		US 5531978 A	02-07-1996
		US 5198208 A	30-03-1993
-----			
FR 2736051	A	03-01-1997	
		AU 6461696 A	30-01-1997
		CA 2222697 A	16-01-1997
		CZ 9704141 A	18-03-1998
		EP 0835140 A	15-04-1998
		WO 9701359 A	16-01-1997
		NO 976098 A	27-02-1998
		NZ 312720 A	29-04-1999
		PL 325531 A	03-08-1998
		SK 173797 A	03-06-1998

### Information on patent family members

PCT/EP 98/08330

Patent document  
cited in search report

Publication  
date

Patent family member(s)

Publication date

FR 2736051 A

US 5886158 A

23-03-1999